skip to main content

BLOOD BIOMARKERS OF RISK FOR SYNUCLEINOPATHY, A VARIANT OF PARKINSON’S DISEASE

Identifiers: SRA: ERP010003
BioProject: PRJEB8960
Alacris Theranostics GmbH: ena-STUDY-Alacris Theranostics GmbH-26-03-2015-08:03:29:772-88
Study Type: 
Other
Abstract: Parkinson’s disease (PD) is a frequent neurodegenerative process at old age. Accumulation and aggregation of the lipid-binding SNARE complex component alpha-synuclein (SNCA) underlies this vulnerability and defines stages of disease progression. Determinants of SNCA levels and mechanisms of SNCA neurotoxicity are intensely investigated. In view of physiological SNCA roles in blood to modulate vesicle release, we studied blood samples from a new large pedigree with SNCA gene duplication (PARK4 mutation), to identify effects of SNCA gain-of-function as potential disease biomarkers. The expression of other Parkinson’s disease gene was not, but CPLX1 mRNA downregulation was correlated with genotype. In global RNAseq profiling of blood from presymptomatic PARK4, bioinformatics detected significant upregulations for platelet activation, hemostasis, lipoproteins, endocytosis, lysosome, cytokine, toll like receptor signalling and extracellular pathways. In PARK4 platelets, stimulus-triggered degranulation was impaired. Strong SPP1, GZMH, and PLTP mRNA upregulations were validated in PARK4. Analysing prodromal stages of general PD, only blood CPLX1 levels were altered in cases with REM sleep behaviour disorder (RBD). Validation experiments confirmed an inverse mutual regulation of SNCA and CPLX1 mRNA levels. In the 3’-UTR of the CPLX1 gene we identified a SNP that is significantly associated with PD risk. In summary, our data provide functional insights into the role and regulation of blood alpha-synuclein levels. The novel blood biomarkers of synucleinopathy may become useful for PD prediction.
Description: Parkinson’s disease (PD) is a frequent neurodegenerative process at old age. Accumulation and aggregation of the lipid-binding SNARE complex component alpha-synuclein (SNCA) underlies this vulnerability and defines stages of disease progression. Determinants of SNCA levels and mechanisms of SNCA neurotoxicity are intensely investigated. In view of physiological SNCA roles in blood to modulate vesicle release, we studied blood samples from a new large pedigree with SNCA gene duplication (PARK4 mutation), to identify effects of SNCA gain-of-function as potential disease biomarkers. The expression of other Parkinson’s disease gene was not, but CPLX1 mRNA downregulation was correlated with genotype. In global RNAseq profiling of blood from presymptomatic PARK4, bioinformatics detected significant upregulations for platelet activation, hemostasis, lipoproteins, endocytosis, lysosome, cytokine, toll like receptor signalling and extracellular pathways. In PARK4 platelets, stimulus-triggered degranulation was impaired. Strong SPP1, GZMH, and PLTP mRNA upregulations were validated in PARK4. Analysing prodromal stages of general PD, only blood CPLX1 levels were altered in cases with REM sleep behaviour disorder (RBD). Validation experiments confirmed an inverse mutual regulation of SNCA and CPLX1 mRNA levels. In the 3’-UTR of the CPLX1 gene we identified a SNP that is significantly associated with PD risk. In summary, our data provide functional insights into the role and regulation of blood alpha-synuclein levels. The novel blood biomarkers of synucleinopathy may become useful for PD prediction.
Center Project: PARK4blood
External Link: /PUBMED:25112678

Related SRA data

Experiments:
40 ( 40 samples )
Runs:
40 (104.6Gbp; 78.1Gb)